HERG Screening Market Overlook
Pune, Maharashtra, India – April 16, 2025 – The global hERG screening market is projected to experience substantial growth in the coming years, driven by increased concerns about drug-induced cardiac arrhythmias and strict regulatory mandates. The global HERG screening market was valued at USD 2,082.76 million in 2023 and is expected to grow at a CAGR of 12.7% during the forecast period.
Market Overview
hERG screening is a critical step in drug safety testing. It focuses on assessing a compound’s potential to inhibit the hERG potassium ion channel, an essential regulator of cardiac action potential. Blockade of this channel can result in QT interval prolongation and fatal arrhythmias like torsades de pointes, leading to the withdrawal of several drugs from the market.
Given its pivotal role, regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) require hERG screening as part of the drug approval process. Pharmaceutical and biotechnology companies are heavily investing in in vitro hERG screening technologies to ensure early detection of cardiotoxicity and prevent costly late-stage drug failures.
The increasing incidence of cardiovascular disorders, greater awareness of drug safety, and advancements in automated and high-throughput screening technologies are major drivers of market growth.
Market Segmentation
The hERG screening market is segmented by product type, ion channel classification, application, and region. Each segment plays a distinct role in driving the industry forward.
By Product Type
- Gene KCNH2: This segment holds the largest market share, driven by its foundational role in cardiac repolarization. The Gene KCNH2 encodes the hERG channel, making it central to all testing assays.
- Mutant KCNH2: Growing interest in personalized and precision medicine is spurring the demand for mutant KCNH2 variants, which are used to understand patient-specific cardiac risks.
By Ion Channel Type
- Voltage-Gated Channels: The most commonly studied group in hERG assays, voltage-gated potassium channels, including hERG, are essential in drug cardiac safety profiling.
- Ligand-Gated Channels: Although not the primary focus in hERG screening, ligand-gated ion channels are gaining attention for their role in broader electrophysiological studies.
- Others: This category includes other specialized ion channels occasionally implicated in drug-induced cardiotoxicity.
By Application
- Antiarrhythmic Drugs: The largest application segment, owing to the intrinsic focus on cardiac ion channels for these treatments. hERG screening is indispensable during development.
- Antipsychotic Drugs: As psychiatric medications often affect cardiac function, rigorous hERG evaluation is required.
- Antibiotics: With some antibiotics known to prolong the QT interval, hERG testing ensures safety and regulatory compliance.
- Others: Includes a wide range of drug categories such as anti-cancer and antihistamines that require cardiac safety assessments.
Browse Full Insights:https://www.polarismarketresearch.com/industry-analysis/herg-screening-market
Regional Analysis
North America
North America is the dominant market, accounting for approximately 40% of global revenue. The region’s leadership is underpinned by its advanced pharmaceutical infrastructure, high healthcare spending, and strict drug safety regulations. The United States, in particular, has a robust pipeline of new drug approvals that necessitate thorough preclinical and clinical testing, including hERG screening.
Europe
Europe holds the second-largest share, about 30% of the global market. Countries like Germany, the UK, and France are hubs for pharmaceutical R&D and clinical trials. The presence of top-tier regulatory bodies, research institutes, and contract research organizations supports sustained growth in this region.
Asia-Pacific
Asia-Pacific is projected to be the fastest-growing market during the forecast period. Increasing R&D investments, expanding pharmaceutical manufacturing capacity, and rising regulatory scrutiny in countries like China, India, Japan, and South Korea are key growth factors. Additionally, the growing number of CROs (Contract Research Organizations) catering to global clients is fueling demand for hERG screening services.
Latin America and Middle East & Africa
These regions currently hold smaller shares but are experiencing steady growth. Brazil, Mexico, the UAE, and South Africa are seeing increased activity in clinical trials and drug development, which is expected to drive gradual demand for cardiac safety testing, including hERG assays.
Key Companies in the hERG Screening Market
The hERG screening landscape is competitive and characterized by both global leaders and emerging innovators. Major players are focused on developing advanced electrophysiology platforms, expanding screening services, and ensuring compliance with international regulatory standards.
Key Market Players Include:
- Abcam PLC
A leading supplier of biological reagents and tools, Abcam provides a range of validated antibodies and kits used in hERG channel research. - AstraZeneca PLC
A global pharmaceutical company, AstraZeneca integrates in-house and outsourced hERG screening in its cardiovascular and central nervous system (CNS) drug discovery efforts. - Aurora Biomed Inc.
Known for their automated patch-clamp systems, Aurora Biomed enhances the throughput and consistency of ion channel screening, including hERG. - AVIVA Biosciences
Specializes in advanced ion channel technology and offers services for preclinical cardiotoxicity testing using proprietary platforms. - Charles River Laboratories Inc.
A major contract research organization, Charles River offers comprehensive safety pharmacology services, including in vitro and in vivo hERG screening assays. - Eurofins-Cerep SA
Provides ion channel profiling services, helping pharmaceutical clients assess the risk of QT prolongation and cardiac toxicity. - Cambridge Bioscience Ltd
Supplies high-quality reagents, assay kits, and cellular models for cardiovascular research, particularly in ion channel screening. - ABR-Affinity BioReagents Inc
Offers a wide array of reagents for neuroscience and cardiovascular research, including those supporting hERG assay development.
Market Drivers and Restraints
Key Drivers:
- Rising Incidence of Cardiovascular Diseases: Heightens the need for drugs with well-established cardiac safety profiles.
- Stringent Regulatory Requirements: hERG screening is a mandated part of drug approval processes across key markets.
- Technological Innovation: High-throughput electrophysiology, 3D cell models, and AI-based predictive screening are advancing capabilities.
Key Challenges:
- High Cost of Equipment and Services: Smaller biotech firms may struggle with the financial burden of advanced screening technologies.
- Variability in Assay Results: Lack of global assay standardization may lead to inconsistencies in data interpretation.
- Regulatory Complexity: Navigating varied international standards can delay development timelines.
Future Outlook
The hERG screening market is poised for sustained growth as drug developers prioritize early identification of cardiotoxic risks. The future will likely witness a rise in:
- In silico screening models that predict hERG channel inhibition.
- 3D tissue models and human stem cell-derived cardiomyocytes for more accurate, physiologically relevant testing.
- Collaborations between CROs and pharmaceutical firms to streamline preclinical safety assessments.
As safety and efficacy continue to be the cornerstones of successful drug development, hERG screening will remain an essential tool. Companies that innovate in assay precision, reduce turnaround times, and provide cost-effective solutions will lead the charge in the evolving global landscape.
Conclusion
The global hERG screening market is entering a dynamic phase, driven by a convergence of regulatory necessity, technological advancement, and the pharmaceutical industry’s focus on cardiac safety. With North America leading the charge and Asia-Pacific emerging rapidly, the market presents immense opportunities for stakeholders. Through continued innovation and strategic collaboration, the hERG screening ecosystem will play a vital role in shaping the next generation of safer, more effective therapeutic agents.
More Trending Latest Reports By Polaris Market Research: